Search CTL/CD8+ T-Cell Epitope Database

Found 7 matching records:

Displaying record number 1271

Download this epitope record as JSON.

HXB2 Location	Tat(2-11) DNA(5834..5863)	Tat Epitope Map
Author Location	Tat(2-11 BRU)
Epitope	`EPVDPRLEPW`	Epitope Alignment
Epitope Name	Tat 1
Species (MHC/HLA)	human(B53)
Immunogen	HIV-1 infection
Experimental methods
Keywords

Notes

Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines -- therefore CTL responses against Tat and Rev were screened using overlapping peptides.
11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide.
EPVDPRLEPW was recognized by four individuals, but only two were B53, thus this epitope can probably be presented by other HLA alleles.

References

Addo2001 Marylyn M. Addo, Marcus Altfeld, Eric S. Rosenberg, Robert L. Eldridge, Mary N. Philips, Kathleen Habeeb, Ashok Khatri, Christian Brander, Gregory K. Robbins, Gail P. Mazzara, Philip J. R. Goulder, and Bruce D. Walker. The HIV-1 Regulatory Proteins Tat and Rev are Freqently Targeted by cytotoxic T Lymphocytes (CTL) Derived from HIV Infected Individuals. Proc. Natl. Acad. Sci. U.S.A., 98(4):1781-1786, 13 Feb 2001. PubMed ID: 11172028. Show all entries for this paper.

Displaying record number 1227

Download this epitope record as JSON.

HXB2 Location	Rev(14-23) DNA(6009..6038)	Rev Epitope Map
Author Location	Rev(14-23 subtype B)
Epitope	`KAVRLIKFLY`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*57:01)
Immunogen
Experimental methods
Keywords	optimal epitope, A-list

Notes

C. Brander notes this is a B*5701 epitope.

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 1273

Download this epitope record as JSON.

HXB2 Location	Rev(14-23) DNA(6009..6038)	Rev Epitope Map
Author Location	Rev(14-23 BRU)
Epitope	`KAVRIKLFLY`	Epitope Alignment
Species (MHC/HLA)	human(B*57:01)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HLA cross-presentation

Notes

Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines -- therefore CTL responses against Tat and Rev were screened using overlapping peptides.
11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide.
This epitope was also recognized by another individual in whom it was restricted by HLA*B5801, an allele closely related to HLA*B5701, suggesting cross-presentation by the two HLA alleles.

References

Displaying record number 1203

Download this epitope record as JSON.

HXB2 Location	Rev(14-23) DNA(6009..6038)	Rev Epitope Map
Author Location	Rev(14-23 subtype B)
Epitope	`KAVRLIKFLY`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*58:01)
Immunogen
Experimental methods
Keywords	optimal epitope, A-list

Notes

C. Brander notes this is a B*5801 epitope.

References

Displaying record number 1272

Download this epitope record as JSON.

HXB2 Location	Rev(14-23) DNA(6009..6038)	Rev Epitope Map
Author Location	Rev(14-23 BRU)
Epitope	`KAVRIKLFLY`	Epitope Alignment
Species (MHC/HLA)	human(B*58:01)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HLA cross-presentation

Notes

Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines -- therefore CTL responses against Tat and Rev were screened using overlapping peptides.
11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide.
This epitope was also recognized by another individual in whom it was restricted by HLA*B5701, an allele closely related to HLA*B5801, suggesting cross-presentation by the two HLA alleles.

References

Displaying record number 1212

Download this epitope record as JSON.

HXB2 Location	Rev(67-75) DNA(8501..8527)	Rev Epitope Map
Author Location	( LAI)
Epitope	`SAEPVPLQL`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(C*05:01)
Immunogen
Experimental methods
Keywords	optimal epitope, A-list

References

Displaying record number 1274

Download this epitope record as JSON.

HXB2 Location	Rev(67-75) DNA(8501..8527)	Rev Epitope Map
Author Location	Rev(69-77 BRU)
Epitope	`SAEPVPLQL`	Epitope Alignment
Epitope Name	Rev SL9
Species (MHC/HLA)	human(Cw8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, supervised treatment interruptions (STI), acute/early infection

Notes

Rev and Tat are expressed early in the virus life cycle and thus may be important targets for CTL against HIV early in infection and for vaccines -- therefore CTL responses against Tat and Rev were screened using overlapping peptides.
11/57 (19.3%) HIV-1+ individuals recognized at least 1 Tat peptide, and 21/57 (37%) responded to at least 1 Rev peptide.
This epitope is the first HIV-specific CTL epitope restricted by HLA-Cw5.
This epitope was recognized by 2/5 individuals expressing HLA-Cw8 and by 5/11 individuals expressing Cw5 allele, which differs from Cw8 by 4 amino acids, suggesting promiscuous presentation of the epitope between those HLA molecules.
Longitudinal data was available for 6 Rev-SL9 responders, who were treated during acute infection, and the response was stable 2 and 12 months after initiation of HAART, measurements by ELISPOT and flow-based intracellular cytokine staining (ICS) were concordant -- in two subjects the response was heightened by transient re-exposure to antigen with treatment interruption at 12 to 14 months.